Four leading cancer research organizations in the United States and Canada announce the opening of patient enrollment to myeloMATCH, a unique portfolio of clinical trials to test precision medicine treatments for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The Alliance for Clinical Trials in Oncology, Canadian Cancer Trials Group, ECOG-ACRIN Cancer Research Group, and SWOG Cancer Research Network are collaborating within the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) to design and lead the trials. They expect to open the trials at hundreds of cancer care sites across the two countries.
The myeloMATCH program will accelerate precision medicine in myeloid malignancies and develop new therapies for patients with these diseases. Its portfolio of primarily phase 2 studies is designed to identify which promising treatments warrant larger, definitive clinical trials outside of myeloMATCH. Three myeloMATCH treatment trials are now open, and numerous others are in development and will open in the coming months.
The myeloMATCH screening protocol is now enrolling adults newly diagnosed with AML or MDS. Researchers hope to eventually enroll 5,000 or more patients. "myeloMATCH provides a portfolio of biomarker -driven treatment trials that adult patients newly diagnosed with AML or MDS will enroll to sequentially over their entire treatment journey," said Harry P.
Erba, MD, PhD, of Duke University School of Medicine. Erba is co-.
,_analyze_by_microscope-Jarun_Ontakrai_8864dd9cfb3b4dff9a913aede7a7c915-620x480.jpg)
